SHORT COMMUNICATION

Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis

Line Kibsgaard 1, Tina Skjold 2, Mette Deleuran 1 and Christian Vestergaard 1

Departments of 1 Dermato-Venereology S and 2 Internal Medicine – Lung Diseases, Aarhus University Hospital, P.P. Ørumsgade 11, DK-8000 Aarhus C, Denmark. E-mail: line-kibsgaard@hotmail.com

Accepted May 13, 2013; Epub ahead of print Oct 25, 2013

Mastocytosis is a group of diseases characterised by accumulation of mast cells in one or more organs including skin, bone marrow, liver, spleen and lymph nodes, skin being the most frequent site of organ involvement. Symptoms are related to continuous activation of mast cells and causes pruritus, flushing, diarrhoea, abdominal pain, musculoskeletal pain, vascular instability, headaches and neuropsychiatric symptoms (1, 2). In children the disease is usually confined to the skin and mostly resolves spontaneously before onset of puberty, whereas in adults, mastocytosis is usually systemic and persist for the lifetime of the patient (1, 2).

Anaphylaxis is a recognised feature of mastocytosis, and symptoms are in both cases related to excessive mast cell mediator release, especially of histamine (3). Here, we present a case concerning a patient with indolent systemic mastocytosis (SM) and recurrent idiopathic anaphylaxis, with full remission of anaphylaxis after onset of treatment with anti-IgE (omalizumab).

CASE REPORT

A 31-year-old man was referred to our outpatient clinic on suspicion of urticaria pigmentosa (UP). For the last 5 years he had noticed a chronically evolving red to brownish macular symmetric exanthema on his trunk and extremities. Physical stimuli, such as heat, resulted in flare-ups with elevation and more intense colour of the elements. Within the last 2 years he had been admitted 3 times to an intensive care unit due to anaphylaxis of unknown cause. Symptoms prior to all episodes were uneasiness, abdominal pain, urge, dizziness and unconsciousness within 10 min. When admitted he presented with hypotension (systolic blood pressure: 75 mmHg), tachycardia, generalised flushing but no urticaria or angioedema. He was treated with standardised anaphylactic regimens and inotropic support until stabilisation. The patient had no previous history of other diseases; no drug abuse and allergies were only described as allergic rhinitis to grass and birch. The patient was equipped with glucocorticoids, antihistamine and epinephrine for future emergency use.

The dermatological examination showed positive Darier’s sign and the diagnosis UP was further confirmed by histology. On suspicion of SM, baseline tryptase was estimated a month after his last anaphylactic reac-

© 2014 The Authors. doi: 10.2340/00015555-1687
Journal Compilation © 2014 Acta Dermato-Venereologica. ISSN 0001-5555
or is triggered by external stimuli such as heat, exercise, drugs or hymenoptera venoms (4). Urticaria and angiooedema, normally present in non-mastocytotic anaphylaxis, are often absent (3, 4, 7, 8).

In mastocytosis the mast cell accumulation is a result of a proliferative disorder of the haematopoietic mast cell progenitor (4). Thus, mast cells may display an atypical morphology and appear spindle-shaped (2). Indolent SM poses a small risk of transforming into malignant haematological disease associated haematologic non-mast cell lineage disease, (ASM and mast cell leukaemia (3% and < 1%, respectively)) with a more aggressive clinical course (2). The result of a high mast cell burden, may also cause severe side-effects, such as collapse of vertebral bodies (9).

As illustrated, it is worth considering SM in patients with recurrent unexplained anaphylaxis, and a diagnostic programme has to involve a thorough skin examination, a serum-tryptase analysis and a bone marrow biopsy. SM is a multidisciplinary disease and requires involvement of both dermatological, allergological, and haematological expertise.

Omalizumab, approved for the treatment of allergic asthma, is a monoclonal antibody, which selectively binds human IgE, and also reduces the expression of FcεRI on circulating basophils and mast cells (10, 11). Thus, omalizumab seems to lower the activity potentials of basophils and mast cells, thereby reducing profound histamine release (10). Consequently, omalizumab has also found favour in the World Allergy Organization treatment guidelines of chronic urticaria (12).

Searching the literature there is only sparse material on treatment with omalizumab in patients with SM and idiopathic anaphylaxis. A case report from 2007 documented full remission of unprovoked recurrent anaphylactic episodes after onset of omalizumab treatment in two patients suffering from SM (13). A few single case reports also demonstrate this tendency (14, 15).

In conclusion, this case suggests that omalizumab may be a rapid, efficient, and well-tolerated treatment for patients with SM and recurrent idiopathic anaphylaxis, resistant to other medications. The use of omalizumab in this patient category is still somewhat experimental, and needs further investigation on larger patient material to become fully integrated in clinical use.

The authors declare no conflicts of interest.

REFERENCES